Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 3Phase 2 2Phase 1/2 2Phase 4 1

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Other solid neoplasm 1

Conditions

Refractory or Relapsed Solid Tumors 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Metastatic Castration-resistant Prostate Neoplasms 1

Interventions

Specimen Handling 45pembrolizumab 40Magnetic Resonance Spectroscopy 32Cyclophosphamide 31Biopsy 31fludarabine 27Cetuximab 19Cisplatin 18Carboplatin 18atezolizumab 15Bevacizumab 15Fluorouracil 14venetoclax 13Radiation 13Leucovorin 13fludarabine phosphate 12Radiotherapy 12Gemcitabine 12Pemetrexed 11Oxaliplatin 11Nivolumab 11Cytarabine 10130-nm albumin-bound paclitaxel 10Prednisone 9Paclitaxel 9Irinotecan 9Fulvestrant 9Radiosurgery 8Platinum 8Immunoglobulin G 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × darolutamide × 30 days × Clear all
NCT05818683 2026-06-05

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Janssen Research & Development, LLC

Phase 1 Recruiting
300 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Neoplasms

NCT05997615 2026-06-04

AMX-500

Vir Biotechnology, Inc.

Phase 1 Recruiting
437 enrolled
Genitourinary

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT07620041 2026-06-02

QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction

Qilu Pharmaceutical Co., Ltd.

Phase 1 Not yet recruiting
48 enrolled
Other solid neoplasm

Refractory or Relapsed Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡